AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
SCYNEXIS, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG002133YY2
3.79▼ 0.02 (-0.66%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
3.81
Day's Range
3.71 – 3.84
52-Week Range
0.57 – 6.09
Volume
55.0K
Avg Volume
391.8K
Share Statistics
Shares Outstanding
Employees
29
Exchange
XNAS
Listed
2014-05-02
Share count as of August 1, 2026

SCYNEXIS, Inc. (SCYX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about SCYNEXIS, Inc. (SCYX)
What is SCYNEXIS, Inc.'s Market Cap?
SCYNEXIS, Inc.'s Market Cap is $37.7M, based on as-reported figures from SEC (XBRL) filings.
What is SCYNEXIS, Inc.'s Price / Sales?
SCYNEXIS, Inc.'s Price / Sales is 2.0×, based on as-reported figures from SEC (XBRL) filings.
What is SCYNEXIS, Inc.'s Revenue (TTM)?
SCYNEXIS, Inc.'s Revenue (TTM) is $19.2M, based on as-reported figures from SEC (XBRL) filings.
What is SCYNEXIS, Inc.'s Net Income (TTM)?
SCYNEXIS, Inc.'s Net Income (TTM) is -$10.2M, based on as-reported figures from SEC (XBRL) filings.
What is SCYNEXIS, Inc.'s Diluted EPS (TTM)?
SCYNEXIS, Inc.'s Diluted EPS (TTM) is -1.03, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SCYXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth-82.8%-100.0%+1808.5%-49.4%
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
% of revenue3408.5%—43.6%2616.5%
Loss from operations
% of revenue-3308.5%—56.4%-2516.5%
Other (income) expense:
Amortization of debt issuance costs and discount
Interest income
Interest expense
Other income——
Warrant liabilities fair value adjustment
Total other income
Net income (loss)
% of revenue3147.7%—65.7%-2572.2%
Net income (loss) per share - basic
Net income (loss) per share - diluted—